PMID- 36323071
OWN - NLM
STAT- MEDLINE
DCOM- 20221128
LR  - 20231202
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Print)
IS  - 1368-8375 (Linking)
VI  - 135
DP  - 2022 Dec
TI  - Prognostic value of CD103(+) tumor-infiltrating lymphocytes and programmed death 
      ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell 
      carcinoma.
PG  - 106226
LID - S1368-8375(22)00515-2 [pii]
LID - 10.1016/j.oraloncology.2022.106226 [doi]
AB  - OBJECTIVES: In an evolving era of immunotherapeutic options for persistent or 
      recurrent laryngeal squamous cell carcinoma (LSCC), there is a need for improved 
      biomarkers of treatment response and survival to inform optimal treatment 
      selection and prognostication. Herein, our primary objective was to explore 
      correlations between tumor infiltrating lymphocytes (TILs) and PD-L1 Combined 
      Positive Score (CPS). Secondarily, we sought to explore their combined 
      association with survival outcomes in patients with persistent or recurrent LSCC 
      treated with salvage surgery. MATERIALS AND METHODS: This was a retrospective 
      cohort study at a single academic medical center. Immunohistochemistry staining 
      for TILs and PD-L1 was performed on a tissue microarray of persistent or 
      recurrent LSCC pathologic specimens. Correlations between TIL subsets and PD-L1 
      CPS were examined using Pearson's correlation coefficient and survival outcomes 
      were analyzed with the Kaplan-Meier method and log-rank tests. RESULTS: Only 
      CD103(+) TILs showed a statistically significant, weakly-positive correlation 
      with PD-L1 CPS (r(2) = 0.264, p < 0.015). No other TIL subsets correlated with 
      PD-L1 CPS in our cohort. The most favorable survival outcomes were seen in 
      patients with pathologic N0 tumors showing high CD103(+) TILs and/or high PD-L1 
      CPS staining. CONCLUSION: Among patients with persistent or recurrent LSCC, 
      CD103(+) TILs only modestly correlated with PD-L1 CPS. A combined biomarker score 
      incorporating CD103(+) TILs and PD-L1 CPS greatly enhanced survival 
      discrimination. This model may have additional utility in predicting the clinical 
      benefit of immunotherapies in persistent or recurrent LSCC in the future.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Smith, Joshua D
AU  - Smith JD
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Bellile, Emily L
AU  - Bellile EL
AD  - Department of Biostatistics, School of Public Health, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Ellsperman, Susan E
AU  - Ellsperman SE
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Heft-Neal, Molly E
AU  - Heft-Neal ME
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Mann, Jacqueline E
AU  - Mann JE
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States; Department of Pathology, University of Michigan, 
      Ann Arbor, MI 48109, United States.
FAU - Birkeland, Andrew C
AU  - Birkeland AC
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Hoesli, Rebecca C
AU  - Hoesli RC
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Swiecicki, Paul L
AU  - Swiecicki PL
AD  - Division of Hematology & Oncology, Department of Internal Medicine, University of 
      Michigan, Ann Arbor, MI 48109, United States; Rogel Cancer Center, University of 
      Michigan, Ann Arbor, MI 48109, United States.
FAU - Worden, Francis P
AU  - Worden FP
AD  - Division of Hematology & Oncology, Department of Internal Medicine, University of 
      Michigan, Ann Arbor, MI 48109, United States; Rogel Cancer Center, University of 
      Michigan, Ann Arbor, MI 48109, United States.
FAU - Schonewolf, Caitlin
AU  - Schonewolf C
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, 
      United States.
FAU - Shah, Jennifer L
AU  - Shah JL
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, 
      United States.
FAU - Mierzwa, Michelle L
AU  - Mierzwa ML
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, 
      United States.
FAU - Rosko, Andrew J
AU  - Rosko AJ
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Stucken, Chaz L
AU  - Stucken CL
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Chinn, Steven B
AU  - Chinn SB
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States; Rogel Cancer Center, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Shuman, Andrew G
AU  - Shuman AG
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Casper, Keith A
AU  - Casper KA
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Malloy, Kelly M
AU  - Malloy KM
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Prince, Mark E P
AU  - Prince MEP
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Wolf, Gregory T
AU  - Wolf GT
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States.
FAU - Thomas, Dafydd G
AU  - Thomas DG
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United 
      States.
FAU - McHugh, Jonathan B
AU  - McHugh JB
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United 
      States.
FAU - Chad Brenner, J
AU  - Chad Brenner J
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States; Department of Pathology, University of Michigan, 
      Ann Arbor, MI 48109, United States; Department of Radiation Oncology, University 
      of Michigan, Ann Arbor, MI 48109, United States.
FAU - Spector, Matthew E
AU  - Spector ME
AD  - Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann 
      Arbor, MI 48109, United States; Department of Radiation Oncology, University of 
      Michigan, Ann Arbor, MI 48109, United States. Electronic address: 
      mspector@med.umich.edu.
LA  - eng
GR  - P30 CA046592/CA/NCI NIH HHS/United States
GR  - T32 DC005356/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20221028
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (CD274 protein, human)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - *Lymphocytes, Tumor-Infiltrating/pathology
MH  - B7-H1 Antigen
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck/pathology
MH  - Retrospective Studies
MH  - *Head and Neck Neoplasms/pathology
MH  - Biomarkers, Tumor
PMC - PMC10099383
MID - NIHMS1866174
OTO - NOTNLM
OT  - CD103
OT  - Combined positive score
OT  - Head and neck
OT  - Larynx
OT  - PD-L1
OT  - Squamous cell carcinoma
OT  - Survival
OT  - Tumor-infiltrating lymphocytes
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/11/03 06:00
MHDA- 2022/11/29 06:00
PMCR- 2023/12/01
CRDT- 2022/11/02 19:14
PHST- 2022/08/10 00:00 [received]
PHST- 2022/10/11 00:00 [revised]
PHST- 2022/10/18 00:00 [accepted]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/11/29 06:00 [medline]
PHST- 2022/11/02 19:14 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - S1368-8375(22)00515-2 [pii]
AID - 10.1016/j.oraloncology.2022.106226 [doi]
PST - ppublish
SO  - Oral Oncol. 2022 Dec;135:106226. doi: 10.1016/j.oraloncology.2022.106226. Epub 
      2022 Oct 28.